As of Thursday close, Exact Sciences Corporation’s (NASDAQ:EXAS) stock was down -$3.42, moving down -4.69 percent to $69.53. The average number of shares traded per day over the past five days has been 1,459,180 shares. 1 time new highs have been achieved over the past 5 days, with a -$7.85 fall in that time frame. In the last twenty days, the average volume was 1,187,425, while in the previous 50 days, it was 1,396,842.
Since last month, EXAS stock retreated -15.06%. Shares of the company fell to $69.26 on 09/21/23, the lowest level in the past month. A 52-week high of $100.77 was reached on 07/19/23 after having rallying from a 52-week low of $29.27. Since the beginning of this year, EXAS’s stock price has risen by 40.44% or $20.02, and marked a new high 23 times. However, the stock has declined by -31.00% since its 52-week high.
EXAS stock investors should be aware that Exact Sciences Corporation (EXAS) stock had its last reported insider trading activity 21 days ago on Sep 01. Condella Sarah, the EVP, Human Resources of the company, disposed of 4,500 shares for $84.36 on Sep 01. It resulted in a $379,620 divestment by the insider. Elliott Jeffrey Thomas sold 30,210 shares at an average price of $82.92 on Aug 21. The insider now owns 0 shares following the transaction. On Aug 07, Gen. Mgr., Precision Oncology Baranick Brian sold 1,350 shares at $85.04 apiece. The transaction was valued at $114,804.
Valuation Metrics
The stock’s beta is 1.43. Besides these, the trailing price-to-sales (P/S) ratio of 5.51, the price-to-book (PB) ratio of 4.10.
Financial Health
In the three months ended June 29, Exact Sciences Corporation’s quick ratio stood at 2.10, while its current ratio was 2.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.76, and the total debt-to-equity ratio was 0.78. On the profitability front, the trailing twelve-month gross margin is 73.50% percent. In the year ended June 29, EBITDA margin amounted to -18.94%, whereas operating margins totaled -17.90%. Based on annual data, EXAS earned $1.51 billion in gross profit and brought in $2.08 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -11.00%. Return on equity (ROE) for the past 12 months was -14.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. EXAS’s revenue rose 17.39% to $602.94 million during the quarter, while net income inched up to $626.92 million. While analysts expected Exact Sciences Corporation to report -$0.51 quarterly earnings, the actual figure was -$0.45 per share, beating the consensus estimate by 11.80%. During the quarter, the company generated -$27.67 million in EBITDA. The liabilities of Exact Sciences Corporation were 3.3 billion at the end of its most recent quarter ended June 29, and its total debt was $2.57 billion. The value of shareholders’ equity is $180.66 million.
Technical Picture
This quick technical analysis looks at Exact Sciences Corporation’s (EXAS) price momentum. With a historical volatility rate of 27.86%, the RSI 9-day stood at 17.29% on 21 September.
With respect to its five-day moving average, the current Exact Sciences Corporation price is down by -10.14% percent or -$7.85. At present, EXAS shares trade -17.80% below its 20-day simple moving average and +8.52% percent above its 100-day simple moving average. However, the stock is currently trading approximately -28.37% below its SMA50 and +49.98% above its SMA200.
Stochastic coefficient K was 4.81% and Stochastic coefficient D was 6.79%, while ATR was 2.46. Given the Stochastic reading of 1.64% for the 14-day period, the RSI (14) reading has been calculated as 24.21%. As of today, the MACD Oscillator reading stands at -3.32, while the 14-day reading stands at -5.26.
Analyst Ratings
Exact Sciences Corporation downgraded its rating on Exact Sciences Corporation (NASDAQ: EXAS) to a Hold in a note to investors on August 02, 2023. The analysts firm previously had a Buy rating on the stock.Exact Sciences Corporation (EXAS) has been rated Overweight by analysts. According to 0 brokerage firms, EXAS is a sell, and 5 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Exact Sciences Corporation stock as buy, with 14 recommending it as overweight.
With a median target price of $110.00, the current consensus forecast for the stock is $90.00 – $130.00. Based on these forecasts, analysts predict Exact Sciences Corporation (EXAS) will achieve an average price target of $110.41.
